KK
NKTR icon

KLP Kapitalforvaltning’s Nektar Therapeutics NKTR Stock Holding History

KLP Kapitalforvaltning’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Buy
7,000
+1,800
+35% +$132K ﹤0.01% 1515
2026
Q1 		$374K Buy
5,200
+1,700
+49% +$96.8K ﹤0.01% 1561
2025
Q4 		$148K Buy
+3,500
New +$196K ﹤0.01% 1943

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KLP Kapitalforvaltning's NKTR Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Nektar Therapeutics (NKTR) stake by 35% in Q2 2026, buying an estimated $132K and bringing the position to 7,000 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

KLP Kapitalforvaltning first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • KLP Kapitalforvaltning held 7,000 shares of Nektar Therapeutics worth $489K as of Q2 2026.
  • KLP Kapitalforvaltning bought 1,800 Nektar Therapeutics shares in Q2 2026, an estimated $132K.
  • Nektar Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1515 holding.
  • KLP Kapitalforvaltning first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.